linjc16/ctgov huggingface dataset:
Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children

Study Overview
=================
Brief Summary
-----------------
Otitis media is one of the most common infections among children and is a complication in about 30% of common colds. The most common complication of acute otitis media is otitis media with effusion. Some studies have reported the effects of montelukast and mometasone nasal spray in treatment of otitis media with effusion. However, current information is inadequate in this issue. The aim of this study was to compare the effectiveness of montelukast and mometasone nasal spray in treatment of otitis media with effusion in children attending Koodakan hospital in Bandar Abbas, Iran.

Official Title
-----------------
Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children

Conditions
-----------------
Otitis Media With Effiusion

Intervention / Treatment
-----------------
* Drug: Monteleukast
* Drug: Mometasone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Children who were between 2 to 6 years old Definite diagnosis of OME with symptoms and examination Exclusion Criteria: • Currently were using corticosteroids or prophylactic monteleukast Chronic pulmonary or cardiac diseases or immune deficiency Allergic rhinitis Hypersensitivity to monteleukast or corticosteroids Avoidance of parents to fill the written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Montelukast<br>4 ml monteleukast daily for one month | Drug: Monteleukast<br>* 4 ml monteleukast daily for one month<br>|
| Active Comparator: Mometasone<br>Inhaled mometasone 1 puff in each side of nose for one month | Drug: Mometasone<br>* Inhaled mometasone 1 puff in each side of nose for one month<br>|
| No Intervention: Control<br>No intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment response | Defined as complete, partial, or no response based on the physician examination | 1 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug side effects | Frequency of Drug side effects as reported by the children or their parents | 1 month |
Evaluation of an Oral Nutritional Supplement

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate gastrointestinal tolerance of an oral nutritional supplement containing a new protein blend in healthy elderly subjects.

Official Title
-----------------
Evaluation of an Oral Nutritional Supplement With a New Protein Blend

Conditions
-----------------
Gastro-intestinal Tolerance

Intervention / Treatment
-----------------
* Other: Study Oral Nutritional Supplement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects will be eligible for the study if they meet all of the following inclusion criteria: Age ≥ 60 and ≤ 90 years Body Mass Index (BMI) > 20 but < 35 Exclusion Criteria: Subjects will be excluded from the study if they meet any of the following criteria: History of diabetes Currently taking or has taken antibiotic within 1 week prior to enrollment Major surgery less than 3 months prior to enrollment in the study Current active malignant disease or was treated within the last 6 months for cancer Immunodeficiency disorder Myocardial infarction within the last 3 months prior to enrollment Chronic obstructive pulmonary disease (COPD) Allergy to any of the ingredients in the study product Aversion to flavor of product being tested Obstruction of the gastrointestinal tract precluding ingestion or absorption of the study product, inflammatory bowel disease, ulcer, gastric reflux disease, short bowel syndrome, or other major gastrointestinal disease Dementia, brain metastases, eating disorders, history of significant neurological or psychiatric disorder Pursuing or has unintentional weight loss or weight gain ≥ 5% in last 4 weeks Medications/dietary supplements/substances that could profoundly modulate metabolism or affect GI motility

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Study Oral Nutritional Supplement<br>2 containers a day of a high calorie, complete, balanced, ready-to-drink oral nutritional supplement with a new protein blend. | Other: Study Oral Nutritional Supplement<br>* Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gastro-Intestinal Tolerance | Self-reported questionnaire | Study Day 1-7 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study Product Compliance | Self-reported number of containers consumed per day | Study Day 1-7 | 
| Weight |  | Study Day 1 and 8 |
Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora

Study Overview
=================
Brief Summary
-----------------
Bacterial resistance to antibiotics has been a growing therapeutic problem since the late 1980s. Resistant strains of pathogenic bacteria can arise through initial selection of resistant strains in the commensal flora. The emergence of fluoroquinolone resistance in the commensal flora will be assessed in 48 healthy volunteers receiving variable doses of ciprofloxacin during 14 days. Emergence of resistance will be correlated to pharmacokinetic characteristics of ciprofloxacin.

Detailed Description
-----------------
Pharmacokinetic/Pharmacodynamic Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora Bacterial resistance to antibiotics has been a growing therapeutic problem since the late 1980s. Resistant strains of pathogenic bacteria can arise through initial selection of resistant strains in the commensal flora. The emergence of fluoroquinolone resistance in the commensal flora will be assessed in 48 healthy volunteers receiving variable doses of ciprofloxacin during 14 days. Emergence of resistance will be correlated to pharmacokinetic characteristics of ciprofloxacin.

Official Title
-----------------
Pharmacokinetic/Pharmacodynamic Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: ciprofloxacin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy volunteers Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ciprofloxacin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of bacterial resistance in commensal flora |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetic/pharmacodynamic relationship |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ciprofloxacin, commensal flora, resistance, Pharmacokinetic
Effect of Vestibular Rehabilitation on Trunk Kinetic and Kinematic Parameters in Patients With Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
The Cawthorne Cooksey exercises and conventional program of physical therapy were administered.

Detailed Description
-----------------
• The Cawthorne Cooksey exercises and conventional program of physical therapy were administered.

Official Title
-----------------
Effect of Vestibular Rehabilitation on Trunk Kinetic and Kinematic Parameters in Patients With Multiple Sclerosis

Conditions
-----------------
Vestibular Rehabilitation in MS

Intervention / Treatment
-----------------
* Other: Cawthorne Cooksey exercise protocol
* Other: conventional vestibular rehabilitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 35-55 years. Ambulatory without assistance. Diagnosed with relapsing-remitting MS by a neurologist, with approximately five relapse attacks in the hemiparesis type with a muscular tone of 1 or 1+ depending on the MAS, or modified Ashworth scale. All individuals were evaluated by a neurosurgeon to confirm central vertigo using test of Dix Hallpike. Degree of MS-related disability based on the enlarged disability status scale, ranging from 2-2.5. Exclusion Criteria: People with musculoskeletal deformities. People with inner ear abnormalities. People with psychiatric disturbances or seizures.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: RCT
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group I<br>received conventional vestibular rehabilitation along with the Cawthorne Cooksey exercise protocol | Other: Cawthorne Cooksey exercise protocol<br>* Cawthorne Cooksey exercise protocol<br>Other: conventional vestibular rehabilitation<br>* conventional vestibular rehabilitation<br>|
| Active Comparator: Group II<br>received conventional vestibular rehabilitation only | Other: conventional vestibular rehabilitation<br>* conventional vestibular rehabilitation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Isokinetic dynamometer (average power) | Assess trunk kinetic and kinematic parameters. | 4 weeks | 
| Isokinetic dynamometer (acceleration time) | Assess trunk kinetic and kinematic parameters. | 4 weeks | 
| Isokinetic dynamometer (deceleration time) | Assess trunk kinetic and kinematic parameters. | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Trunk kinetic and kinematic parameters, Vestibular rehabilitation, Multiple Sclerosis.
Barriers to the Implementation of Complete Insulin Order Sets

Study Overview
=================
Brief Summary
-----------------
The major purpose of this Quality Improvement project is to begin to address the issues surrounding glycemic control in the hospital setting by collecting accurate, reliable and verifiable data on the occurrence of hyperglycemia (BG >300 mg/dL), and whether or not CIO is used (immediately before and 72 hours after the BG >300 mg/dl).

Official Title
-----------------
Barriers to the Implementation of Complete Insulin Order Sets in the Management of Individuals With Hyperglycemia or Diabetes at Park Nicollet Methodist Hospital

Conditions
-----------------
Hyperglycemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Park Nicollet Methodist Hospital patient recorded BG > 300 mg/dL during the study data collection period admitted to general floor hospital units Exclusion Criteria: birth center intensive care units eating disorder unit pediatric patients < 18 years of age patients receiving insulin infusions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| hyperglycemia<br>hospitalized patients with BG >300 ml/dL | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glucose levels |  | 72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| type of insulin treatment |  | 72 hours |
A Trial on Contrast-enhanced Ultrasound Versus Conventional Ultrasound Guided Biopsy of Liver Neoplasms

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to estimate the clinical value of contrast-enhanced ultrasound in percutaneous biopsy for liver occupied lesion.

Detailed Description
-----------------
The patients with liver neoplasms who need receive percutaneous biopsy were randomized into contrast-enhanced ultrasound(CEUS) group and conventional ultrasound(US) group.The aims include: Comparison the diagnostic accuracy rate, specificity and sensitivity between CEUS and US group. Comparison the diagnostic accuracy rate specificity and sensitivity between smaller(<3cm) and larger(≥3cm) nodule group. To explore operating strategy of contrast-enhanced ultrasound guided biopsy. To evaluate economic efficiency of contrast-enhanced ultrasound guided biopsy compared with conventional ultrasound guided biopsy.

Official Title
-----------------
The Multi-center Study of Percutaneous Focal Liver Lesions Biopsy Guided by Contrast-Enhanced Ultrasound

Conditions
-----------------
Liver Neoplasms

Intervention / Treatment
-----------------
* Other: CEUS guided biopsy
* Other: US guided biopsy
* Device: Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with liver occupied lesion who cannot be diagnosed by imaging examination or need pathological results Exclusion Criteria: severe anemia PLT<60000/mm3,prothrombin activityprothrombin time activity<70% women during menstruation, pregnancy, child birth and baby nursing period patients with severe mental disorder cardiopulmonary failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CEUS guided biopsy<br>Biopsy was operated under contrast-enhanced ultrasound-guided | Other: CEUS guided biopsy<br>* Biopsy was operated under contrast-enhanced ultrasound-guided.<br>Device: Ultrasound<br> <br> |
| Other: US guided biopsy<br>Biopsy was operated under conventional ultrasound-guided | Other: US guided biopsy<br>* Biopsy was operated under conventional ultrasound-guided.<br>Device: Ultrasound<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnostic accuracy | diagnostic accuracy=（true positive+ ture negative)/number of parcitipants | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biopsy, contrast-enhanced ultrasound
Vestibular Function After Chemoradiotherapy for Nasopharyngeal Carcinoma

Study Overview
=================
Brief Summary
-----------------
Nasopharyngeal carcinoma (NPC) is usually treated with chemoradiotherapy. While the effects of this treatment on cochlear function is well characterized, its effect on vestibular function is not well studied. In this study the investigators will study the vestibular function of 50 patients undergoing chemoradiotherapy for NPC both before and after treatment in order to better define its effects. All patients will undergo a validated questionnaire (dizziness handicap index), posturography, audiometry and vestibular-evoked myogenic potentials.

Official Title
-----------------
Vestibular Function After Chemoradiotherapy for Nasopharyngeal Carcinoma

Conditions
-----------------
Nasopharyngeal Carcinoma

Intervention / Treatment
-----------------
* Radiation: Chemoradiotherapy for nasopharyngeal carcinoma


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older. Biopsy-proven NPC. About to undergo chemoradiotherapy with intensity-modulated radiotherapy (IMRT). Exclusion Criteria: Pregnancy. Prior vestibular dysfunction.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study group<br>Patients older than 18 who are planned to undergo chemoradiotherapy for nasopharyngeal carcinoma. | Radiation: Chemoradiotherapy for nasopharyngeal carcinoma<br>* Note that this is standard care for NPC and patients are not assigned to different intervention groups. All patients in the study will receive the same treatment (chemoradiotherapy) and will be observed for changes in vestibular function.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective dizziness and vestibular dysfunction using the dizziness handicap index |  | 6 months after completion of treatment | 
| Hearing level using standard audiometry |  | 6 months after completion of treatment | 
| Objective vestibular function using posturography |  | 6 months after completion of treatment | 
| Vestibular saccular function using vestibular-evoked myogenic potentials |  | 6 months after completion of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vestibular function, chemoradiotherapy
Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate whether a low level of serum omentin-1 is associated with carotid atherosclerosis and mediated by inflammation.

Detailed Description
-----------------
Atherosclerotic cardiovascular disease is markedly increased in chronic kidney disease. There are a lot of risk factor, along with conventional risk factors. Serum onemtin-1 is a adipokine and suggested as a new marker for vascular disease.It has some anti-atherogenic properties. Studies investigating serum omentin-1 level have usually conducted in patients with diabetes mellitus.

Official Title
-----------------
The Relationship Between Serum Omentin-1 and IL-6 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

Conditions
-----------------
Non-diabetic Chronic Kidney Disease, Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: between ages of 18 - 65 years old chronic kidney disease of stage 3-4 Exclusion Criteria: Chronic kidney disease of stage 5 The history of ischemic cardiovascular disease (myocardial infarction, unstable angina, stroke, peripheral artery disease, or cardiovascular revascularization) Severe heart failure Stage 2 hypertension Diabetes mellitus Corticosteroid therapy Severe hepatic disease Smoking Inflammatory disease Acute infectious disease Malignancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Case Group<br>Patients with chronic kidney disease of stage 3-4. | |
| Control group<br>30 healthy subject | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
omentin-1, carotid atherosclerosis, kidney disease